HUM
Strong BuyFull HouseFLAGHumana Inc. · Healthcare · United States · $46.3B · Avg Vol: $378M/d
Full House: Strong business, sensible price, market agrees. The rare full house.
Humana has strong momentum at M79 with a buyback on file, but value at V47 is below the calibrated floor and quality Q55 is modest, so stage one fails, consistent with the Mexican line flagged earlier in this run.
The ranks quoted here are from the day it was written; today's Quality, Value and Momentum are the bars above.
ABOUT HUMANA INC.
Read
Humana Inc. is a leading U.S. health and well-being company focused on integrated health care plans, particularly for Medicare and Medicaid beneficiaries. The company's extensive clinical care services and strong focus on value-based care models differentiate it in the competitive health insurance landscape. Humana's significant market share in the growing Medicare Advantage sector provides a stable and expanding revenue base.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 92.9B | 106.4B | 117.8B | 129.7B | 11.8% | 145.7B | 162.8B | 168.5B | 14.0% |
| EPS | 22.20 | 20.09 | 10.01 | 9.87 | -23.7% | 10.57 | 5.27 | 9.54 | -1.7% |
| Shares | 125.0M | 122.2M | 120.6M | 120.6M | -3.5% | 120.1M | — | — | — |
| Debt | 11.1B | 11.7B | 11.7B | 12.4B | 3.6% | 14.7B | — | — | — |
| Equity | 15.3B | 16.3B | 16.4B | 17.7B | 4.9% | — | — | — | — |
| Op CF | 4.6B | 4.0B | 3.0B | 921.0M | -41.4% | 2.5B | — | — | — |
| Inv CF | -1.0B | -3.5B | -3.0B | 2.3B | — | — | — | — | — |
| Fin CF | -1.9B | -856.0M | -2.5B | -1.2B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of HUM are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| HUM | Humana Inc.(you) | $46.3B | 89 | Strong Buy |
| CNC | Centene Corporation | $32.0B | 93 | Strong Buy |
| CI | The Cigna Group | $73.7B | 92 | Strong Buy |
| ELV | Elevance Health, Inc. | $85.5B | 90 | Strong Buy |
| CVS | CVS Health Corporation | $119.0B | 93 | Strong Buy |
| OSCR | Oscar Health, Inc. | $9.4B | 98 | Strong Buy |
| UNH | UnitedHealth Group Incorporated | $352.7B | 90 | Strong Buy |
| MOH | Molina Healthcare, Inc. | $10.4B | 71 | Buy |
| CLOV | Clover Health Investments, Corp. | $2.2B | 79 | Buy |
| PGNY | Progyny, Inc. | $2.0B | 98 | Strong Buy |
Peer medians: ROE -31.0% · P/E 25.0x · Gross margin 58.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.